Improving the value of molecular testing: current status and opportunities in colorectal cancer precision medicine

References

1. 1.↵
   2. Lang GT,
   3. Jiang YZ,
   4. Shi JX,
   5. Yang F,
   6. Li XG,
   7. Pei YC, et al.

   Characterization of the genomic landscape and actionable mutations in Chinese breast cancers by clinical sequencing. Nat Commun. 2020; 11: 5679.

   OpenUrl
2. 2.↵
   2. Biller LH,
   3. Schrag D.

   Diagnosis and treatment of metastatic colorectal cancer: a review. JAMA. 2021; 325: 669–85.

   OpenUrlCrossRefPubMed
3. 3.↵
   2. Van Cutsem E,
   3. Köhne CH,
   4. Hitre E,
   5. Zaluski J,
   6. Chang Chien CR,
   7. Makhson A, et al.

   Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009; 360: 1408–17.

   OpenUrlCrossRefPubMedWeb of Science
4. 4.↵
   2. Benson AB,
   3. Venook AP,
   4. Al-Hawary MM,
   5. Azad N,
   6. Chen YJ,
   7. Ciombor KK, et al.

   Rectal cancer, version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022; 20: 1139–67.

   OpenUrlCrossRefPubMed
5. 5.
   2. Cervantes A,
   3. Adam R,
   4. Roselló S,
   5. Arnold D,
   6. Normanno N,
   7. Taïeb J, et al.

   Metastatic colorectal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023; 34: 10–32.

   OpenUrlCrossRefPubMed
6. 6.↵
   2. Yuan Z,
   3. Weng S,
   4. Ye C,
   5. Hu H,
   6. Zhang S,
   7. Yuan Y.

   CSCO guidelines for colorectal cancer version 2022: updates and discussions. Chin J Cancer Res. 2022; 34: 67–70.

   OpenUrl
7. 7.↵
   2. Guo L,
   3. Wang Y,
   4. Yang W,
   5. Wang C,
   6. Guo T,
   7. Yang J, et al.

   Molecular profiling provides clinical insights into targeted and immunotherapies as well as colorectal cancer prognosis. Gastroenterology. 2023; 165: 414–28.

   OpenUrl
8. 8.↵
   2. Datta J,
   3. Smith JJ,
   4. Chatila WK,
   5. McAuliffe JC,
   6. Kandoth C,
   7. Vakiani E, et al.

   Coaltered Ras/B-raf and TP53 is associated with extremes of survivorship and distinct patterns of metastasis in patients with metastatic colorectal cancer. Clin Cancer Res. 2020; 26: 1077–85.

   OpenUrlAbstract/FREE Full Text
9. 9.↵
   2. Janssen KP,
   3. Alberici P,
   4. Fsihi H,
   5. Gaspar C,
   6. Breukel C,
   7. Franken P, et al.

   APC and oncogenic KRAS are synergistic in enhancing Wnt signaling in intestinal tumor formation and progression. Gastroenterology. 2006; 131: 1096–109.

   OpenUrlCrossRefPubMedWeb of Science
10. 10.↵
    2. Sparks AB,
    3. Morin PJ,
    4. Vogelstein B,
    5. Kinzler KW.

    Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer. Cancer Res. 1998; 58: 1130–4.

    OpenUrlAbstract/FREE Full Text
11. 11.↵
    2. Cisowski J,
    3. Sayin VI,
    4. Liu M,
    5. Karlsson C,
    6. Bergo MO.

    Oncogene-induced senescence underlies the mutual exclusive nature of oncogenic KRAS and BRAF. Oncogene. 2016; 35: 1328–33.

    OpenUrlCrossRefPubMed
12. 12.↵
    2. Antoniotti C,
    3. Boccaccino A,
    4. Seitz R,
    5. Giordano M,
    6. Catteau A,
    7. Rossini D, et al.

    An immune-related gene expression signature predicts benefit from adding atezolizumab to FOLFOXIRI plus bevacizumab in metastatic colorectal cancer. Clin Cancer Res. 2023; 29: 2291–8.

    OpenUrl
13. 13.↵
    2. Ratovomanana T,
    3. Nicolle R,
    4. Cohen R,
    5. Diehl A,
    6. Siret A,
    7. Letourneur Q, et al.

    Prediction of response to immune checkpoint blockade in patients with metastatic colorectal cancer with microsatellite instability. Ann Oncol. 2023; 34: 703–13.

    OpenUrl
14. 14.↵
    2. Turajlic S,
    3. Litchfield K,
    4. Xu H,
    5. Rosenthal R,
    6. McGranahan N,
    7. Reading JL, et al.

    Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis. Lancet Oncol. 2017; 18: 1009–21.

    OpenUrlCrossRefPubMed
15. 15.↵
    2. Maby P,
    3. Galon J,
    4. Latouche JB.

    Frameshift mutations, neoantigens and tumor-specific CD8(+) T cells in microsatellite unstable colorectal cancers. Oncoimmunology. 2016; 5: e1115943.
16. 16.↵
    2. Loupakis F,
    3. Depetris I,
    4. Biason P,
    5. Intini R,
    6. Prete AA,
    7. Leone F, et al.

    Prediction of benefit from checkpoint inhibitors in mismatch repair deficient metastatic colorectal cancer: role of tumor infiltrating lymphocytes. Oncologist. 2020; 25: 481–7.

    OpenUrlCrossRefPubMed
17. 17.↵
    2. Middha S,
    3. Yaeger R,
    4. Shia J,
    5. Stadler ZK,
    6. King S,
    7. Guercio S, et al.

    Majority of B2M-mutant and -deficient colorectal carcinomas achieve clinical benefit from immune checkpoint inhibitor therapy and are microsatellite instability-high. JCO Precis Oncol. 2019; 3: PO.18.00321.
18. 18.↵
    2. Crisafulli G,
    3. Sartore-Bianchi A,
    4. Lazzari L,
    5. Pietrantonio F,
    6. Amatu A,
    7. Macagno M, et al.

    Temozolomide treatment alters mismatch repair and boosts mutational burden in tumor and blood of colorectal cancer patients. Cancer Discov. 2022; 12: 1656–75.

    OpenUrlCrossRef
19. 19.↵
    2. Liu YT,
    3. Sun ZJ.

    Turning cold tumors into hot tumors by improving T-cell infiltration. Theranostics. 2021; 11: 5365–86.

    OpenUrlCrossRefPubMed
20. 20.↵
    2. Magee MS,
    3. Abraham TS,
    4. Baybutt TR,
    5. Flickinger JC Jr.,
    6. Ridge NA,
    7. Marszalowicz GP, et al.

    Human GUCY2C-targeted chimeric antigen receptor (CAR)-expressing T cells eliminate colorectal cancer metastases. Cancer Immunol Res. 2018; 6: 509–16.

    OpenUrlAbstract/FREE Full Text